Clinical Trials Logo

Clinical Trial Summary

This is a randomized, placebo-controlled, study of SPI-62 in subjects with ACTH-dependent Cushing's syndrome caused by a non-adrenal tumor. Subjects will receive each of the following 2 treatments for 24 weeks: SPI-62 and matching placebo with the option of long-term extension.


Clinical Trial Description

This is a multicenter, randomized, placebo-controlled, Phase 2 study to evaluate the pharmacologic effect, efficacy, and safety of SPI-62 in subjects with ACTH-dependent Cushing's syndrome. Each subject who provides consent and meets all inclusion and exclusion criteria will participate in a screening period (Days -35 to -8), a baseline period (Days -7 to -1), and a treatment period (Day 1 of Week 1 to Day 168 ± 3 days of Week 24) and, the option of long-term extension. Subjects have the option to continue with the study on active study drug and return to the site every 3 months for blood tests and study drug dispensing. The visits may be conducted remotely if testing can be arranged. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05307328
Study type Interventional
Source Sparrow Pharmaceuticals
Contact
Status Active, not recruiting
Phase Phase 2
Start date September 1, 2022
Completion date December 1, 2025

See also
  Status Clinical Trial Phase
Not yet recruiting NCT05503433 - Effect of Maternal Cortisol Levels on Fetal Heart Rate Patterns
Completed NCT03856502 - Influence of Intrathecal Dexamethasone Administration for Proximal Femoral Fractures N/A
Recruiting NCT05759637 - Type 2 Diabetes, Obesity and Cortisol Excess
Active, not recruiting NCT06307782 - The Effect of Oral Whey Consumption on Insulin Resistance, Cortisol, Crp, Albumin Level and Healing Quality Before Total Hip Arthroplasty N/A
Completed NCT03412591 - The Efficacy of Suvorexant in Treatment of Patients With Substance Use Disorder and Insomnia: A Pilot Open Trial Phase 2/Phase 3
Recruiting NCT05021380 - Salivary Immune/Stress Biomarkers Among Children
Completed NCT03242304 - Neuroactive Steroids in Acute Ischemic Stroke N/A